Tezcat Biosciences

Tezcat Biosciences is pioneering a macropinocytosis-targeting drug delivery platform to treat aggressive, Ras-mutated cancers and other diseases. The company's core innovation is a protein-drug conjugate that is selectively internalized by cancer cells exhibiting high levels of macropinocytosis, a nutrient-scavenging process, while sparing healthy cells. This approach aims to overcome the limitations of receptor-dependent targeting and offers flexibility in payload selection, including small molecules, PROTACs, and nucleic acids. As a private, pre-revenue company, Tezcat is advancing an internal pipeline and is open to strategic partnerships to expand the platform's applications.

A receptor-independent drug delivery platform that exploits the cellular process of macropinocytosis. It uses a designed protein carrier (approx. 10 kDa) conjugated to therapeutic payloads (e.g., small molecules, PROTACs, siRNA) that is selectively internalized by diseased cells exhibiting high macropinocytic activity, such as Ras-activated cancer cells.

Tezcat competes in the crowded oncology drug delivery space against companies developing antibody-drug conjugates (ADCs), ligand-directed therapies, and nanoparticle systems. Its differentiation is its receptor-independent mechanism targeting a fundamental cancer cell metabolic process, but it must demonstrate superior selectivity or efficacy to gain traction.